Filariasis: Clinical Trials

11 trials for Filariasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Completed 11
Phase 21Completed 1

Follow Filariasis: new trials by email Literature Review of Filariasis trials Research Report on Filariasis

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Moxidectin, Ivermectin, Albendazole - Onchocerciasis
Phase 3CompletedMedicines Development for Global Health129792021-05-032026-03-03
Moxidectin for LF, Cote d'Ivoire (DOLF)
Ivermectin, Diethylcarbamazine, Albendazole - Lymphatic Filariasis
Phase 3CompletedWashington University School of Medicine1642020-08-202026-01-29
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis
Phase 3CompletedThe Task Force for Global Health2352019-01-152021-06-24
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1 - Trachoma, Yaws
Phase 3CompletedLihir Medical Centre200002018-10-012019-02-28
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis
Phase 3CompletedThe Task Force for Global Health2202018-06-192021-06-24
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis
Phase 3CompletedThe Task Force for Global Health2192018-02-162021-03-17
Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Albendazole - Helminthiasis, Filariasis
Phase 3CompletedUniversity of Washington3577162017-10-042026-01-22
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Ivermectin, Albendazole - Malaria, Lymphatic Filariasis
Phase 2 / Phase 3CompletedColorado State University27122015-06-012019-01-04
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
IVM plus ALB, IVM - Onchocerciasis
Phase 3CompletedUniversity Hospitals Cleveland Medical Center3752014-06-012019-04-26
IVM Alone vs ALB + IVM Against Onchocerciasis
Ivermectin, Albendazole - Onchocerciasis
Phase 3CompletedUniversity Hospitals Cleveland Medical Center2722012-04-012017-08-29
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
Moxidectin, Ivermectin - Onchocerciasis
Phase 3CompletedMedicines Development for Global Health14972009-04-012018-01-31

Narrower conditions

Elephantiasis, Filarial (6)  ·  Onchocerciasis (4)  ·  Lymphedema (3)  ·  Helminthiasis (1)  ·  Malaria (1)  ·  Neglected Diseases (1)  ·  Onchocerciasis, Ocular (1)  ·  Scabies (1)  ·  Strongyloidiasis (1)  ·  Trachoma (1)  ·  Yaws (1)

Broader conditions

Infections (11)  ·  Nematode Infections (11)  ·  Parasitic Diseases (11)  ·  Secernentea Infections (11)  ·  Spirurida Infections (11)  ·  Helminthiasis (10)  ·  Vector Borne Diseases (7)  ·  Hemic and Lymphatic Diseases (6)  ·  Lymphatic Diseases (6)  ·  Mosquito-Borne Diseases (6)  ·  Skin Diseases (5)  ·  Skin Diseases, Infectious (5)  ·  Skin Diseases, Parasitic (5)  ·  Skin and Connective Tissue Diseases (5)

Interventions

Albendazole (6)  ·  Ivermectin (6)  ·  Doxycycline (3)  ·  moxidectin (3)  ·  Diethylcarbamazine (2)  ·  Albumins (1)  ·  Azithromycin (1)  ·  Intravital Microscopy (1)

Sponsors

The Task Force for Global Health (3)  ·  Medicines Development for Global Health (2)  ·  University Hospitals Cleveland Medical Center (2)  ·  Colorado State University (1)  ·  Lihir Medical Centre (1)  ·  University of Washington (1)  ·  Washington University School of Medicine (1)

Countries

Ghana (3)  ·  Côte d’Ivoire (2)  ·  Democratic Republic of the Congo (2)  ·  India (2)  ·  Benin (1)  ·  Burkina Faso (1)  ·  Liberia (1)  ·  Malawi (1)  ·  Mali (1)  ·  Papua New Guinea (1)  ·  Sri Lanka (1)  ·  United States (1)

Top investigators

Eric Ottesen, MD (3)  ·  Benjamin Koudou, PhD (2)  ·  Brian D. Foy, PhD (1)  ·  Catherine Bjerum, MD, MPH (1)  ·  Christopher L King, MD, PhD (1)  ·  James W Kazura, MD (1)  ·  Judd L Walson, MD, MPH (1)  ·  Lucy John, MD (1)  ·  Nicholas O Opoku, MBChB, MSc (1)  ·  Philip Budge, MD, PhD (1)  ·  Roch K Dabire, PhD (1)  ·  Toki Pascal Gabo, MD (1)  ·  Tony Ukety, MD, DO, MPH (1)

Results publications

PMID 11873261, PMID 22610930, PMID 32228663, PMID 10656038, PMID 29346377, PMID 29361335, PMID 30878222, PMID 33137100, PMID 33930024, PMID 33979325, PMID 34226233, PMID 34281614, PMID 34403424, PMID 35476631, PMID 35701056, PMID 35803632, PMID 36461087, PMID 36897877, PMID 36917597, PMID 37036890, PMID 37616301, PMID 37721964, PMID 37899143, PMID 38175837, PMID 38319937, PMID 39242171, PMID 39380086, PMID 40345209, PMID 40752908, PMID 42264499, PMID 42684913, PMID 42848323

NIH funding

R01AI155739 (1)